SCM
KURA icon

Stonepine Capital Management’s Kura Oncology KURA Stock Holding History

Stonepine Capital Management’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-25,000
Closed -$144K – 69
2025
Q2 		$144K Buy
+25,000
New +$153K 0.14% 53

Other funds holding KURA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Stonepine Capital Management's KURA Position: Q3 2025 in Review

Stonepine Capital Management sold out of Kura Oncology (KURA) in Q3 2025, closing a stake of 25,000 shares — an estimated $144K sold.

Stonepine Capital Management first reported a position in KURA in Q2 2025 and held it in 1 quarter. The position peaked at $144K in Q2 2025. 200 funds tracked by Wall St. Rank hold KURA as of Q3 2025.

  • Stonepine Capital Management reported no remaining Kura Oncology position as of Q3 2025 after selling out during the quarter.
  • Stonepine Capital Management sold 25,000 Kura Oncology shares in Q3 2025, an estimated $144K.
  • Stonepine Capital Management first reported a position in Kura Oncology in Q2 2025 and held it in 1 quarter.
  • Stonepine Capital Management's Kura Oncology position peaked at $144K in Q2 2025.
  • 200 funds tracked by Wall St. Rank held Kura Oncology as of Q3 2025.

Based on Stonepine Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.